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INTRODUCTION 
Today a lot of attention is given to investments in the technological sector, especially in 
Russia. Such organizations as RUSNANO, FIEP, Skolkovo Foundation, State Corporation Bank 
for Development and Foreign Economic Affairs (Vnesheconombank), Russian Venture 
Company, Russian Direct Investment Fund, Agency for Strategic Initiatives, Russian Foundation 
for Technological Development are contributing to the diversification of the economy. Each of 
listed companies is dealing with the new ventures, which are creating new high-tech products to 
compete on the market.  
Biotechnology is one of the most attractive technological industries for investors in 
Russia and all over the world (Russia biotechnology report, 2014). According to the expert 
analysis biotechnologies that have a beneficial effect on human body and quality of life have the 
potential to be one of the most profitable industries in the 21st century. The key organization in 
Russia that invest in biotechnologies are Institute of Human Stem Cells, Bioprocess Capital 
Ventures, Bind Therapeutics, Selecta Biosciences and HimRar. 
Biotechnology is a complex term, which is usually includes three areas of the research: 
biomedicine, industrial biotechnologies, and agrobiotechnologies. Biomedicine is the 
development of new pharmaceutical products, vaccines, molecular diagnostics and so on. 
Industrial biotechnologies include industrial processes with the use of biotechnological reactors, 
microbial recycling of waste, producing of biofuel and biodegradable plastics. 
Agrobiotechnologies is the technologies of remediation of soil, increasing the tolerance and 
productivity of plants and son on. This paper focuses mainly on the evaluation of biomedical 
startups.  
The investment analysis of young firms and especially technological ventures is being 
one of the most complicated questions in the literature devoted to the investment practices. 
Those companies have a limited history, no revenues; they operate in the very uncertain 
environment and sometimes don't even have markets for their products. They require special 
methods of investment analysis in other words valuation techniques and risk management tools 
that are different from already existing approaches.  
There is a gap today between theoretical literature and real practice in terms of methods 
that are used for valuation and risk management. Most of the practitioners use classical DCF 
approach, which has a number of limitations when dealing with technological investments. It 
fails to capture the value of flexibility of the project and usually doesn't provide an adequate 
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treatment of risks. There are more complex and sufficient techniques that can be used to value 
the technological investment. 
Real options analysis (ROA) is the extension of the financial options theory. It applies the 
same methodology to assess the real business problems. Basically, the real option is the 
opportunity or choice that becomes available within the particular investment. Like a financial 
option, it gives a right but not an obligation to undertake an investment. This instrument has an 
advantage over other methods of valuation because it enables to capture the flexibility of 
managerial decisions and consider multiple sources of risk.  
In this paper, the ROA technique is implemented for investment analysis of the particular 
biotechnological project in order to give recommendations for managers of the particular 
investment fund. The research also might be interesting for managers who work on similar 
problems.  The goal of this paper is to develop recommendations to improve the process of 
investment analysis including valuation and risk management of biotechnological startups 
applying the methodology of real options. To reach this goal the following objectives should be 
accomplished:  
– Provide an overview of existing methods of investment analysis of technological and 
biotechnological projects; 
– Review real options method applicability to investment analysis of technological and 
biotechnological projects;    
– Formulate methodology for real options analysis of biotechnological startups; 
– Apply the formulated methodology to conduct the investment analysis of NWTTC 
(RUSNANO group) portfolio project PolySeed; 
– Develop recommendations for improvement the process of investment analysis of 
biotechnological startups. 
The Research is organized as follows. The first chapter of the paper is devoted to 
literature analysis of the topic. There is a description of existing methods of valuation the 
technological projects as well as most important stages of each technology development, it’s 
intrinsic risks and methods of risk management. 
 Furthermore, in the first chapter the concept of Real Options is presented as well as 
approach of other authors to the ROA process. There is also the discussion about applicability of 
real options in technological sphere, observation of common types of real options models and 
review of other papers that are devoted to ROA in biotechnological sphere. 
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The second chapter provides the methodology of the research that includes three steps: 
strategic analysis, risk analysis, and quantitative analysis. The strategic analysis implies the 
framing of the ROA problem. On the second step, the two broad categories of risks that can be 
applied to biotechnological startup are analyzed: market risks and technological risks. On the 
third stage, the three methods of valuation including DCF valuation, decision tree method, and 
Real Options Analysis are described in order to estimate the value of the project. The chosen 
method of Real Options Analysis, the process of its implementation, and necessary assumptions 
are presented in this chapter.  
In the third chapter, the methodology is applied to the particular project from the 
portfolio of North-West Technology Transfer. There is an overview of the project, its external 
environment, and potential risks. The formulated methodology is applied in the chapter. In the 
result the certain implications that can give managers more flexibility in the process of 
investment analysis of biotechnological startups are proposed.  
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CHAPTER 1. LITERATURE REVIEW 
1.1 Investment analysis of technological projects 
Everything is pretty much clear with the valuation of firms with well-established 
operations and long selling history. There are plenty of models and approaches to analyze their 
market price and sources of the value. Things are getting more complex when we start thinking 
about young companies and especially about those, which are operating in the technological 
environment. There are some analysts who argue that such a firms cannot be valued at all.  
When valuing a firm or investment project the analysts draw on information from three 
sources (Damodaran, 2006): The current financial state of the firm or project, the past history of 
the firm in terms of earnings and market prices, and the firm’s competitors or peer group to 
measure how much better or worse a firm is than its competitors. While you would optimally 
like to have substantial information from all three sources, it is normal to substitute more of one 
type of information for less of the other. 
In the case of technological startups, an analyst will run into serious information 
problems. First, these firms usually have not been in existence for more than a year or two, 
leading to a very limited history. Secondly, these companies usually have very few assets in 
place and have all value in the growth potential, which is very difficult to estimate due to the 
highly uncertain environment. Thirdly, this firms often develop the break through innovation 
products, which don’t have any market data or even competitors or peers. 
Given all these information constraints its getting obvious that special methods of 
valuation are required for technological investments. In the next paragraph an overview of 
existing approaches to financial valuation of technology startups will be given. After that the 
important issue of stages in new venture development will be discussed. Investment analysis 
includes not only valuation of the startup but also the consideration of risks so the typical 
uncertainties of the technological project are also presented in this part of the research. 
1.1.1 Valuation methods of technological investments 
DCF method 
The most common method for investment valuation is DCF approach (Beninnga and 
Tolkowsky, 2002). In the case of valuation of young technological companies, the method can 
also be called Venture Capitalist Net Present Value (VC-NPV). Generally, this method takes free 
cash flows generated in the future by a specific project or company and discounts them to derive 
a present value. When DCF calculations produce values that are higher than the initial 
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investment, this usually indicates that the investment may be worthwhile and should be 
considered. 
In the traditional DCF method, the discounting value that is usually used is the weighted 
average cost of capital (WACC). In the VC-NPV approach the discounting factor is usually very 
high, 20%-100% (Timmons and Spinelli, 2004), 40%-75% (Westland, 2002, p.136). For 
example, in North-West Technology Transfer Center (NWTTC) the usual discounting factor for 
financial models is relatively high because of the higher risk of new venture creation is 
incorporated in this discount rate. 
While the DCF method is widely used by practitioners and there are experts who argue in 
favor of its applicability for new ventures (Damodaran, 2006, p. 891), it is being criticized a lot 
in the financial literature. Furthermore, this trend is not new, first attempts were made by Mayers 
and Tynbull in1977 or Hodder and Riggs in 1985. From more fresh articles on that topic, there 
are Boer 2000, Benninga and Tolkowskiy 2002, Steffens and Douglas 2007, Schachter and 
Mancarella 2016. There are two main limitations of DCF analysis: It doesn’t explicitly consider 
multiple scenarios and it doesn’t provide a flexible treatment of risk.  
The first limitation is derived from the DCF assumption of passive management meaning 
that investment is made only once at the beginning of the project without the ability to postpone 
or dynamically make changes to the investment project. Given assumption doesn’t satisfy the 
dynamic nature of technological startups where everything changes very fast. The DCF approach 
analyses single (most likely) scenario and ignores hidden opportunities and risks. Moreover, in 
the technological sphere a lot of spendings are irreversible and represent high sunk costs for a 
firm. So that costs are “locked-in” within a project but will affect future decisions that will be 
made. 
The second limitation is that the only treatment of higher risk in DCF is simply the 
assigning of a high discount rate so it fails to capture the value created by managerial flexibility 
in the treatment of risks. The DCF model fails to distinguish between market risk and firm 
specific risk so in the result it is good only in treatment of the first one but much of the risks 
associated with a new venture is specific (McGrath and MacMillan, 2000). Furthermore, a time-
based penalty (i.e. discount rate) is not appropriate for most specific risks, which largely vary in 
a lumpy manner at discrete times rather than continuously over time.  
Despite all critics the DCF method is still a good benchmark for investment analysis and 
the base for all other more complicated techniques. The doubtful benefit of this method is 
simplicity, which prevents analyst from the mistakes and enables to get the solutions very fast.  
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The Market Comparables method 
The given method uses data from public companies and private market transactions to 
estimate value. It gives adequate indications of what market can pay for the company. There are 
different ways to use the information from the comparables to estimate the value of the subject 
property. One approach is to consider each factor one at a time and compare the averages to the 
subject. A better approach, if sufficient data are available, is to build a statistical model to the 
data, for example, by using multiple regression. The model can be used to assess the marginal 
effect of each factor in conjunction with the effects of the others.  
The Market Comparables method can be applicable to the valuation of new ventures and 
it is, arguably, delivers value estimates that come close to what investors are willing to pay, but 
unfortunately, there are some problems with this approach. It is rather obvious that the method is 
not working with disruptive technologies but it also may not be applicable to sustaining 
technologies.  
Mostly, because data about comparable companies is difficult to obtain. It's not easy to 
find companies on the startup market themselves and it is even harder to get access to the deal 
terms which are usually kept under wraps. Furthermore, if the company and its data would be 
found it is not necessary that it is at the same stage of the development with our company. 
Hence, it is highly unlikely that suitable market data is available for establishing a valuation 
using the market comparables method. 
First Chicago method  
Rather than limiting the analysis to a success scenario, the First Chicago method (Smith, 
2011) uses probability-weighted scenarios to come up with a more reliable estimate of expected 
(in the statistical sense) cash flows, rather than just the optimistic cash flows used in the VC 
method. These expected cash flows are then discounted using a more realistic cost of capital, 
rather than the high hurdle rates used in the VC method. If the scenario probabilities are 
correctly weighted, the appropriate discount rate is identical to the one that would be used in 
DCF valuation by the. A benefit of the First Chicago method is that it requires the analyst to 
think about the range of possible outcomes for the venture and their probabilities.  
Typically, three scenarios are used: the “best guess” (most likely, median case); the “best 
case” (optimistic) and the “worst case” (pessimistic). For each of the three scenarios, 
management must estimate the subjective probability that the scenario will occur and the cash 
flows for each scenario are estimated as for VC-NPV method. The valuation is equal to the 
expected (probability-weighted) NPV of the three scenarios.  
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The advantages of this approach are that some of the risks associated with the venture are 
identified and different types of risk are separated and explicitly assessed. As such, this approach 
acts as a starting point for dealing with the risks in the more flexible manner. An important 
consequence of dealing with many sources of risk explicitly is a reduction in the sensitivity of 
the valuation to the discount rate – which is now being used to account for less of the overall risk 
facing the venture.  
However, there are some important limitations of this method. The most crucial is that 
the method doesn’t provide any framework of how to value potential flexibility in managerial 
decisions. 
Decision tree approach 
Decision Tree Analysis (DTA) has a long tradition in management science and has been 
around since the 1960 (Raiffa, 1968). Here we discuss not the full convention of ‘decision 
analysis’ that involve constructing (or defining) the utility function of the decision maker, but 
rather the simple DTA which involves calculating the expected NPV using a decision tree.  
Long back the decision trees were the only tool to capture the value of flexibility under 
uncertainty. However, they use they popularity was limited due to complexity (Diallo, 2000). 
DTA handles the sequential risk with discrete outcomes while there are difficulties in the 
situations with a wide range of outcomes. DTA is also good when dealing with firm’s specific 
risk (Steffens and Douglas, 2007) and is not good in terms of assessing the market risk.  
According to Dzuma 2012, the classical methods of valuation may give a biased result in 
the situations like: 
– Projects that have the option to delay to collect more precise information about current 
state of the market; 
– Projects the implementation of which gives opportunities to launch another project; 
– Projects during the implementation process of which will be needed to make the 
decisions to change the volume of the production; 
– Projects that can be abandoned; 
– Multi-stage projects in which implementation of one phase depends on the successful 
completion of the previous one; This situation is typical for investments with substantial 
initial costs, for example, to carry out research (pharmaceutical industry, biotechnology, 
real estate).  
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1.1.2 Stages of new project development 
Every single startup company is going through several stages during its development. 
Why it matters in the context of valuation? Because the perception of risk, nature of options will 
change from stage to stage. For example, in the early stages, a startup will be riskier for investors 
as it has limited operation history without any revenues. 
There are usually about five or six stages that are mentioned in the literature (Smith, 
2011) (Damodaran, 2006). In this paper, six stages will be discussed: Opportunity stage, 
research, and development, start-up, early growth, rapid growth and exit. Each stage is 
characterized by its own options and sources of value.  
Figure 1. Stages of new venture development. 
 
Source: Smith, 2011 
Opportunity stage  
The main activities on this stage are: to obtain seed financing, assess strategic 
opportunities, determine organizational structure and form and to prepare the business plan. 
Opportunity staged is not characterized by the significant capital inflows. The source of value 
that the company has at this stage is entirely the future growth. The options that the project 
usually has are to continue to the next stage, modify the concept or abandon the project. 
Research and development stage 
On this stage the company is obtaining R&D financing, building research team, 
conducting R&D, assessing and upgrading business plan. The source of value on this stage can 
be in the form of patent or other intellectual property but not in the form of real revenues. The 
options for the venture are to continue to the next stage, extend stage financing, modify R&D 
strategy, abandon the project. 
Startup stage 
On the start-up stage venture should obtain the financing to initiate revenue generation, to 
initiate the production, to build sales and marketing team and to acquire facilities and equipment. 
Beginning from this stage the company can be compared with other companies on the market. 
On this stage there are options to continue to the next stage, to modify production or financing, 
to modify marketing and to abandon the project.  
 
 
Opportunity R&D Startup Early-growth Rapid-growth Exit
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Early growth stage  
On this stage companies usually obtain financing for further growth, work toward 
revenue breakeven, expand team and facilities if needed. The main source of revenue still relies 
on the further growth but already with a portion of existing assets. The options are to continue to 
the next stage, extend stage financing or to abandon the project. 
Rapid growth stage 
The only difference with previous stage is that the company on the rapid growth stage is 
reaching economic breakeven and working towards proven viability to attain investments. On 
this stage, the operating history of the company can be already used in the valuation. The options 
of the company continue to the next stage or to extend the financing. 
Exit stage 
On the last stage companies usually do activities to establish a continuing financing such 
as IPO, acquisitions, buyouts and so on. The source of valuation on this stage is mainly the 
existing assets. The only option that the ventures have on this stage is to choose the form of exit. 
1.1.3 Risks of a technological project 
Every company or project is influenced by the different factors of risk. This influence can 
be both negative and positive. That is why the process of risk management is so crucial 
especially for investment projects. Risk management is the process of identification, analysis and 
either acceptance or mitigation of uncertainty in investment decision-making.  The stages of 
identification and assessment of risk are the important part of this research. 
In traditional financial literature, there is a distinction between market and firm-specific 
risk. Market risk is that part of risk correlated with the market (known as systematic risk), 
whereas firm-specific risk (known as private or unsystematic risk) is unique to the firm 
(Copeland et al, 2005).  Dixit and Pindyck in their book Investment Under Uncertainty 
distinguish between two form of uncertainty for the technological project: “technical” 
uncertainty and “input cost” uncertainty. 
Technical uncertainty refers to the probabilities of costs and probabilities of 
accomplishing technical success; a firm reduces this type of risk only through investment. 
Technical uncertainty creates pressure on the firm to invest immediately. Delays, at best, incur a 
discounting penalty and, at worst, expose the firm to the risk of competitive preemption. Input 
cost uncertainty relates to factors exogenous to the firm. No amount of investment makes a 
difference in this form of uncertainty, which creates pressure on the firm to delay investment 
until information is revealed with the passage of time.  
 16 
In McGrath, 1997 the third type of risk was suggested and called “external” risk. This 
type of risk is presented when sources of uncertainty are caused by external factors, not technical 
in nature and can be influenced by the strategic action of a company. These are risks that 
technological company can hedge and that are consequently influencing the value of a 
technological option. 
Figure 2. Factors influencing the value of technology option. 
 
 Source: McGrath,1997 
The risk associated with the level of demand is related to the market size for the 
technology (disruptive technologies) and the market share the firm will capture (disruptive and 
sustaining technologies). These uncertainties are both related to the market factors and actions of 
the particular firm.  
The speed of adoption is the very important factor that affects the size of the revenue 
stream. People are slow to change their existing, are resistant to making time investments which 
are necessary to learn the new way of doing things, and reluctant to throw their old assets. So the 
adaptation usually takes longer that was anticipated in the beginning. When adaptation is slow 
additional resources are needed to push the product on the market. Moreover, competitors have 
more time to respond or even leapfrog the idea. 
Blocking occurs when the business is preventing from accessing customers, sales 
channels or other critical resources as the result of actions of the third party that can be 
competitors, government, etc. Massive regulatory hurdles, for example, affect biotechnology 
industry, on the stage of R&D. The problem with blocking is that it can either stop the business 
 17 
or require enormous investments and managerial decisions to continue. 
Expropriation is similar to blocking in a way that firm faced a threat from the more 
powerful external players but it differs in the outcome. When it is blocked, the firm is denied 
access to critical resources and markets. Under expropriation, however, the firm is required to 
give away a portion of its cash flows. For instance, such a threat may come from the 
government, which can increase the tax burden of the firm in the national interest. 
The next portion of uncertainties is dealing with sustainability of revenue streams. 
Duration of competitive advantage influenced by the market response. Matching occurs when 
after the success in addressing important customer problem, competitors are able to address the 
same problem but doing it with technology or other recourses proprietary to themselves. 
Imitation is also an important threat because the product, which is easy to imitate, is more likely 
be able to preserve price premiums or sustainable market share.   
The next big group of uncertainties is related to the cost side. The obvious cost factors 
include investment to create and distribute the product or service, the creation of production 
facilities, hiring and organization of staff, and marketing expenses. These investments can be 
broadly called infrastructure investments and, of course, to the extent that the availability of such 
infrastructures is uncertain now or in the future, the expected costs of commercialization and 
their variance will be greater. 
Two other categories of costs in the model are more specific and occur when the 
additional product is needed to support the existing one. This could be in the form of parallel 
supportive technology or other cospecialized assets. The greater the potential is to deploy 
existing parallel technologies or uniquely owned cospecialized assets in conjunction with the 
proposed technology, the greater the value of the technology option will be. 
Spillover effect refers to the situation when a company utilizes the developing technology 
to enter one modest market with the to target other markets when this technology is sufficiently 
well developed. In this case, technological uncertainties are reduced because the company 
already have the relevant experience.  
Technology life-cycle status matters a lot in terms of risks, as in the periods of 
incremental changes firms innovate in the context of dominant design. That means that key 
dimensions of the market have been established, the customers have been educated, and 
coexisting technologies share a common architecture.  In the satiation like this, clearly, the risks, 
as well as the costs, are lower, while in the periods of disruptive change firms need to make more 
investments.  
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1.2 Real options for investment analysis of technological projects 
1.2.1 Concept of Real Options 
Literally, the real options approach is the extension of financial option theory to options 
on real (nonfinancial) assets. While financial options are detailed in the contract, real options 
embedded in strategic investments must be identified and specified. Moving from financial 
options to real options requires a way of thinking, one that brings the discipline of the financial 
markets to internal strategic investment decisions (Amram and Kulatilaka, 1999). 
The real option is right but not the obligation to undertake certain management initiatives. 
It can be seen as call or put option on underlying incentive. The connection between vital 
parameters of a financial call option and a real option are given in table 1. 
Table 1  
Parameter comparison of a Financial and a Real option 
Financial option on the stock Real option on a project 
Current value of the stock Present value of expected cash flows 
Exercise price Investment cost 
Time to expiry Life of project opportunity 
Stock price volatility Uncertainty of the project 
Risk free interest rate Risk free interest rate 
Source: Hull, 2006. 
Real options investments are characterized by sequential, irreversible investments made 
under conditions of uncertainty (Dixit and Pyndyk, 1994). The framework suggests that in the 
beginning investor purchases the option and then, during the course of the holding period, the 
value of option changes in response to external events. Normally, when market volatility 
increases the option price is also increases (Oriani and Sobrero 2008). 
As it was discussed previously the NPV approach has a number of important limitations. 
That was Stewart Mayers who said: “Strategic planning needs finance. Present value calculations 
are needed as a check on strategic analysis and vice versa. However, standard discounted cash 
flow techniques will tend to underestimate the option value attached to growing profitable lines 
of business. Corporate finance theory requires extension to deal with real options» (Mayers, 
1984). Moreover, the benefit of real options analysis is that it incorporates volatility, whereas 
decision trees (which rely on NPV analysis) only compute expected values. 
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1.2.2 The Real Options Process 
In the literature, there are different approaches to illustrate the implementation of the Real 
Options Analysis. In Morano (2014) the three basic stages of Real Option Process were 
discussed: Risk analysis, strategic analysis and quantitative analysis. 
The path is organized in a “cascade” mode, so the results of each phase form the starting 
point of the next, the connections between the various steps do not allow a clear separation and 
give rise to a linear iterative process, which can sometimes require the return on the factors 
already analyzed, in order to deepen the study or broaden the spectrum of investigation. 
In Mun (2002) the three main stages of Real Option Analysis implementation are 
extended to 8 steps:  
Qualitative management screening  
On this step management decides which projects, assets or strategic initiatives are viable 
for further analysis, in accordance with the firm’s mission, vision, goal or overall business 
strategy. The insights are created as management frames to complete a problem. Also on this 
stage, various risks of the project are identified. 
Time-Series and Regression forecasting 
The future is forecasted using time-series analysis or multivariate regression analysis if 
historical or comparable data exist. Otherwise, other qualitative forecasting methods may be 
used (subjective guess, growth rate assumptions, expert opinions, Delphi method, and so forth). 
Base case Net Present Value analysis 
For each project that passes the two initial stages, a discounted cash flow model is 
created. This model serves as the base case analysis, where a net present value is calculated 
using the traditional approach of using the forecast revenues and costs, and discounting the net of 
these revenues and costs at an appropriate risk-adjusted rate. 
Monte Carlo simulation 
Because, the static DCF produces only a single- point estimate result, there is often a 
little confidence in its accuracy given that cash flows are highly uncertain. To better estimate the 
actual value of a particular project, Monte Carlo simulation should be employed next. 
Real Options problem framing 
The next critical step is to frame the problem within the context of ROA. Based on the 
overall problem identification occurring during the initial qualitative management screening 
 20 
process, certain strategic options would have become apparent for each particular project. The 
strategic options may include, the option to abandon, to switch, to contract, to expand and so 
forth. 
Real Options modeling and analysis 
Through the use of Monte Carlo simulation, the resulting stochastic discounted cash flow 
model will have a distribution of values. In ROA, it is assumed that the underlying asset is the 
future profitability of the project, which is the future cash flow series. An implied volatility of 
the future cash flows or other underlying assets can be calculated through the results of Monte 
Carlo simulation. Usually, the volatility is measured as the standard deviation of the logarithmic 
returns on the free cash flow stream. Using the implied volatility and present value of future cash 
flows the ROA is performed to obtain the project’s strategic option values. 
Portfolio and resource optimization 
This is the optional step of which analysis is done on multiple projects. This is actual 
only for companies who have portfolio of projects because there are opportunities for hedging 
and diversifying risks through the portfolio. 
Reporting and update analysis 
Real options analysis assumes that the future is uncertain and that management has the 
right to make midcourse corrections when these uncertainties become resolved or risks become 
known. Therefore, when it happens, the analysis should be revisited to incorporate the decisions 
made or revising any input assumptions. 
1.2.3 Real options in technological sphere 
There is a discussion on whether ROA (Real Options Analysis) is a good instrument to 
value the investments in the technology in general and more particularly in young technological 
startup companies. In Adner and Levinthal 2004, it is stated that there are two critical features of 
the ROA process: 1) The value of the option and and the underlying asset is exogenous to the 
investor's activity – the investor cannot take steps to make the intrinsic characteristics of the 
asset more attractive; 2) The market signal of option value is readily observable and is 
independent of investors’ behavior. 
These two statements imply that in the industries where market and technological agenda 
are flexible such as in the most technological industries the implementation of ROA would be 
problematic. There would be too many degrees of freedom for ruling out success. However, the 
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firm can have a stricter action mandates, the more formalized milestones, organizational 
structures that are more tolerant to failure and so on, to cope with these difficulties. 
The next portion of criticism comes from the notion that ROA is good at treatment of 
market risk but not the firm-specific risk, which investors usually want to be compensated for. 
This comes from the original ROA method that identifies a replicating portfolio of traded 
securities that match the volatility of the investment. Nonetheless, it is extremely hard to find 
such a security for any technological investment (Steffens and Douglas, 2007). 
Another and more common method for volatility determination is the risk neutral 
valuation this method is often easier to implement. Both methods build on no arbitrage 
opportunity and assume that all investors are neutral towards risk, which is the basis for a risk 
neutral valuation. This allows all assets in the market to be valued regardless of the different 
individual risk preferences. This assumption is valid in a financial setting under the assumption 
that risk can be hedged or completely eliminated at every time step by buying and selling the 
right quantity of shares and options, known as a risk-neutral portfolio (Hull, 2006).  
However, since RO are usually not traded assets, a portfolio of RO and shares cannot be 
traded to hedge an investor’s risk, invalidating the risk-neutral assumption (Hugonnier and 
Morellec, 2007) (Sick, Gamba 2010). In Schachter and Mancarella 2016 it is suggested to use 
different discount rates depending on the level of risk associated with the cash flow. Possibly this 
rates may be different at distinctive points in time to reflect the different level of uncertainty 
while the future unfolds.  
The uncertainty estimation is very important part of real option analysis. In the Black-
Scholes model one can use either historic volatility or the implied volatility for calculating the 
option value. The historic volatility of the stock can be computed by estimating the standard 
deviation of continuous price return of a series of recent stock prices. As an alternative option, 
the stock’s volatility can be derived from the market price of a stock by inverting the Black-
Scholes formula. The volatility parameter that is estimated using the latter method is called the 
implied volatility. 
When implementing real option models to the technological projects, estimating the 
volatility parameter for the underlying asset is much more difficult because the relevant market 
data is rarely available. In case of technological projects it is more appropriate to estimate the 
volatility of project value rather than volatility of comparable stock that usually do not exist. 
Since the underlying asset for a real option is the gross project value it is important that one use 
the volatility of underlying asset value. There are a lot methods present in the financial literature 
to estimate the volatility of underlying cash flows. 
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ROA methods can be classified into three types: Analytical or continuous methods, 
discrete time or lattice models and simulation models. The basic features of each method and it’s 
applicability to valuation of technological investments will be discussed next in this paragraph. 
Analytical methods 
All analytical methods are mostly the modifications of the Black-Scholes model which is 
described below. They allow deducing an analytical price of the option by creating a 
mathematical expression to value its dynamics over time. Analytical methods are exact, quick, 
and easy to implement with the assistance of some basic programming knowledge. ! = #$% &' − )*(,-./)%(&1)                                         (1) 2 = )*(,345)% −&1 −	#$% −&' 																																																	(2) 
&' = ln	( 	#$) ) + 34 + :12 5< 5 																																																							(3) &1 = 	&' − : 5																																																																			(4) 
Where c is a value of the call, p is a value of the put, #$ is the price of underlying asset, K 
is the exercise price, rf – risk free rate, : is volatility of the asset, T is the time of expiry of the 
option and finally N is the cumulative probability distribution for a normal distribution.  
However, these kinds of methods are criticized a lot in the classical ROA literature and 
literature devoted to implementation of ROA in the technological sphere. Analytical methods are 
also called closed-form because they are difficult to explain, as they tend to apply highly 
technical stochastic calculus mathematics. 
They are also very specific in nature, with limited modeling flexibility. Closed-form 
methods are very precise for European options but can be only approximations for American 
options. Moreover, many more complex compound and Bermudan options cannot be solved with 
analytical methods. 
The “Black-Scholes” model is by far the most numerically tractable model we have for 
valuing options, but are its assumptions appropriate for ROA? Almost not, because it assumes 
continuous trading, constant interest rate, and no exercise before final option maturity. The 
model is considering only one uncertainty, or at most two correlated once, which limits its 
implementation on difficult technological projects. 
The “Black-Scholes equation” relies on the uncertainty following a stochastic process 
with constant mean and volatility over time. On technological markets have changing mean and 
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volatility over long timescales (Brigo, 2007). Again assumption is better suited for operational 
decisions of technological or engineering companies, as in Kitapbayev, 2013. 
Simulation methods 
These types of models are based on Monte-Carlo simulations. Implementation of the 
simulation gives an opportunity to incorporate into the ROA many scenarios and several sources 
of volatility. Simulation models can price options for any stochastic process with different 
probability distributions, thus extending the valuation to assets with non-normal or non- 
lognormal returns too. 
The example of simulation approach is the Datar-Mathews method (Datar and Mathews, 
2007). The method provides an easy framework to conduct ROA of a project simply by using the 
average of positive outcomes for the project. The approach can be seen as an extension of the net 
present value (NPV) multi-scenario Monte Carlo model with an adjustment for risk aversion and 
economic decision-making. 
As it was discussed above the terms N(d1) and N(d2) are used in the calculation of the 
Black–Scholes formula, and are variables related to operations on lognormal distributions. The 
Datar–Mathews method does not use N(d1) or N(d2), but instead typically solves the option 
problem by means of Monte Carlo simulation applicable to many different types of distributions 
inherent in real option contexts. When the Datar–Mathews method is applied to assets with 
lognormal distributions, it becomes possible to visualize graphically the operation of N(d1) and 
N(d2). 
However, despite of it’s methodological excellence simulations methods are still 
complicated for practical usage and what is more important they don’t provide clear strategic 
framework for managers.    
Lattice methods 
To solve the American option problem, Cox, Ross and Rubenstein developed the 
binomial tree which provides discrete time approximation to the Geometric Brownian Motion 
process (GBM) and computing the value of exercising an option earlier than at expiry. At every 
time period, the value from immediately exercising the option (known as the exercise value) is 
compared with the value from holding this option one extra time period in the future (known as 
the continuation value which is based on the expected value of the option). 
The basic assumption of the binomial model for pricing options is that the options market 
is the (supposed) efficient, i.e., speculators are unable to obtain excessive profits from the 
combination with the basic tools and options with the simultaneous buying and selling of both. 
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Provided that, if known to the base price, the possibility that price changes in one direction or 
another, risk-free interest rate, you can calculate the price of the option with the set deadlines. 
There are generally two types of methods to calculate an option in the lattice framework: 
replicating portfolio and risk-neutral valuation. The replicating portfolio method is based on 
finding a security in the market that has the same or very similar cash flow as the project the 
company is considering undertaking. Based on the law of one price, if the so called twin security 
and the investment have those characteristics they will have the same value.  
Risk neutral valuation is a more common method than the replicating portfolio approach 
to value real options and often easier to implement. Both methods build on no arbitrage 
opportunity and assume that all investors are neutral towards risk, which is the basis for a risk 
neutral valuation. However, in the risk neutral valuation the search for a twin security is 
unnecessary since the method approaches the valuation from the theory of option pricing.  
Lattice methods are convenient, very popular and are analogous to dynamic programming 
as they rely on backward-recursion through Bellman's optimality principle. However, they have 
some important limitation such as: difficulty with incorporating multiple volatilities, the 
underlying asset should follow lognormal distribution and practical flows of replicating portfolio 
and risk-neutral probability methods.  
1.2.4 Common types of real options in the technological sphere 
There are plenty of real options types or as they are also called Real Options models. The 
most common are the Option to defer, Option to expand, Option to contract, Option to abandon 
and Option to switch. The more complex real options models still exist, including compound 
options, which are basically the combinations of the five most common options. Compound 
options are widely used in technological sphere because usually projects in this field have 
multiple stages depending on the success of previous stage. In this paragraph the main types of 
real options will be observed. 
Option to defer 
An option to defer enables a company to defer its investment decision for some period of 
time or until more information about the project is available. It can be seen as the American call 
option on the project value. For example, we can imagine a company that has a new product 
under development and protected by the patent, then there is an option to wait the favorable 
conditions on the market. This option is widespread in technological project because they 
operate in the uncertain markets. The value of an option to defer can be denoted as max(V – I, 0), 
where I is initial investments and V is the present value of the projects cash flows. When the 
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value of the project will exceed the value of the investments the company will exercise its option 
and launch or go ahead with the project. 
Option to expand  
This option is enables the company to expand its current production. The option to 
expand can be interpret as an American call on the value of the additional output. In 
technological sphere the Option to expand is usually involved into compound option. For 
example, company that has the production facilities is waiting for a patent and wants to expand 
the production if it will get it. Intrinsic value of an expansion option is denoted as max(pV-I-V, 
0), where V is the present value of the projects cash flow, p is the percent of expansion of the 
project and I is the initial investment cost.  
Option to contract   
 Is the opposite of the expansion option and enables the company to reduce the output if 
market conditions turn out to be unfavorable. Option to contract is analogous to American put 
option on the capacity installed. For example, the company that is operating in an uncertain 
environment, where demand for its product is decreasing. Then the management has the option 
to shut down one of their production lines and therefore to decrease their maintenance and 
production cost. The value of the right to decrease an output is max(I – pV, 0) where I is the cost 
saved by contracting, p is the percent of reduction of the project and V the present value of the 
projects cash flow.  
Option to Abandon 
If a project turns out to be unsuccessful the company has the right to close it and may be 
sell it for a salvage value instead of keeping it going and facing losses. Option to Abandon, can 
be seen as the American put on the project value and denoted as max(V-S, 0) where S is the 
salvage value. In technological industry it is the common case when larger company for salvage 
value merges one company with the bright R&D but unsuccessful business model. 
Option to Switch 
This type of option enables the company to switch between either input materials or 
output products. It is particularly valuable in uncertain environment where prices can fluctuate 
very frequently. With a switching option it can be possible to choose from one project to another 
as if the previous project is unsuccessful but has some knowledge that the second project can 
benefit from. A switching option may give companies a considerable competitive advantage.  
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Compound option 
Compound option analysis refers to the situation when existing of one option generates 
another. For example, at the R&D stage of a new drug company has several stages of 
technological development, clinical tests and receiving the final approval. Every step depends on 
the previous stage because it can be either terminated or continued depending on technological 
success of the drug.  
A compound option derives from the value of another option but not from the value of 
underlying asset. The first investment creates right but not the obligation to create next 
investments which in turn gives the possibility to make further investment and so on. A 
compound option can be sequential or parallel (Kodukula and Papudesuk, 2006). If a company 
must exercise an option to create another one, it is considered as sequential option and in 
opposite case the compound option is parallel. 
1.2.5 Real options in biotechnological sphere 
There are a number of representative studies in the financial literature that were aimed to 
value the biotechnological firm using the Real Options Analysis (Cassimon 2004, Fujiwara 
2015, Kellog 2000, Loch 2002, Wang 2015, Zabolotskij 2008). The given studies apply different 
approaches to the problem. The approaches mainly differ by the ROA models that are used and 
the types of options that are estimated. 
In Kellog (2000) and Zabolotskij (2008) the binomial lattice method with risk-neutral 
valuation advocated by Cox, Ross and Rubenstein (1979) was used. The key insight of this 
approach is that because the option value is independent of investor’s risk preferences, the same 
value will be obtained even when everyone is assumed to be risk neutral. This important 
assumption simplifies the calculations by eliminating the need to estimate the risk premium in 
the discount rate. Also, it is important that the method enables to estimate the market value of the 
project rather than a subjective or private value. 
Another approach is to evaluate options with dynamic programming (Loch 2002, Wang 
2015). The given method doesn’t require asset replication which is beneficial in case of 
technological projects. The drawback of the dynamic programming approach is that it does not 
address the question of the correct risk-adjusted discount rate. Dynamic programming requires 
an exogenously specified discount rate that reflects the decision maker's risk attitude. Moreover, 
this approach doesn't provide a decision framework for the mangers but rather calculates the 
final value of an option. 
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Concerning the nature of Real Options that are applicable for biotechnological projects 
the most common one is the option to abandon the project. Almost in every case the 
management have a possibility to close the project and receive a salvage value from selling the 
patent rights or equipment or other assets. The value of such flexibility is contributing to the 
present value of the project.  
Another model is growth option which is substitutable to the abandon option so they can 
be presented in the project at the same time.  The idea for the growth option is that engaging in 
the development of the project is similar to purchasing a call option on the value of the 
subsequent project. By engaging in the development of the biotech product, the company earns 
the right but not the obligation, to conduct the subsequent development.  
The third most common real option in biotechnological sphere is the option to defer the 
project. For instance, if one of the stages of the development process was not successful 
management can may not just close the project but try again or wait until the more favorable 
conditions on the market. 
The most accurate way of analyzing multi stage projects within the real options 
framework is the sequential compound option model (Cassimon 2004). In the given model every 
step of the development process is described as a European call option. Only after exercising one 
option the company have a right but not the obligation to continue the next stage. The series of 
options lattices are considering one after another and it gives more accurate results than creation 
of only one lattice.  
The specify of a biotechnological sphere or even every technological development is the 
possibility to estimate the Rainbow Option. There is such possibility because technological and 
market uncertainties are not correlated with each other. The Rainbow Option means that the 
option has multiple uncertainties in the case of biotechnologies it is the probability of proceeding 
to the next round of development and possibility to commercialize the technology.   
Summary 
The given chapter is devoted to the review of existing approaches to investment analysis 
of technological startups and description of Real Options concept as well as specifics of its 
implementation in technological area. Such approaches to valuation of technological projects 
like DCF analysis, First Chicago, market comparables, and decision tree methods do not allow to 
capture the full flexibility of technological investments. Moreover, these approaches do not value 
properly the multi-stage projects in which implementation of one phase depends on the 
successful completion of the previous one, which is typical for biotechnological sphere. 
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Every technological startup has the number of stages or milestones including opportunity 
stage, R&D stage, startup stage and other that are different in terms of uncertainties. The risks 
can be classified as market uncertainties systematic or firm specific and technical uncertainties. 
The real options approach is the extension of financial option theory to options on real 
(nonfinancial) assets. The real option is right but not the obligation to undertake certain 
management initiatives. It can be seen as a call or put option on underlying incentive. The ROA 
process includes risk assessment, net present value calculation, real options problem framing and 
quantitative analysis.  
The ROA technique can be applied to technological projects, among three main methods 
of real options the binomial (lattice) method is most common and convenient for managers as it 
allows to build a consistent framework of the project. There are several different types of real 
option types or models such as the option to defer, option to expand, the option to contract, the 
option to abandon, option to switch and the compound option. 
There are a number of papers that were aimed to value the biotechnological firm using 
the Real Options Analysis. According to these studies, the most accurate method to value the 
biotechnological development is to use sequential compound rainbow option. The sequential 
compound option exists when the project has multiple stages and each step depends on the 
previous. The rainbow option refers to the situation when the project has different uncertainties, 
for instance, technological and market uncertainties.    
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CHAPTER 2. METHODOLOGY  
The new ventures that are focused on creation of new biotechnological products have the 
number of common traits. These features can be called the specifics of biomedical startups. They 
refer to the process of product research and development, specificity of risks and the way of 
“cashing out” the investments. These specific traits will affect the design of real options and are 
important in further analysis. 
This chapter is devoted to the methodology of real options analysis process of new 
biotechnological startups. As it was discussed above the ROA process has several required steps. 
These are Strategic analysis, Risk analysis, and Quantitative analysis. In this chapter the 
methodology will be described according to given sequence. 
2.1 Strategic analysis  
In the stage of strategic analysis of biotechnological project management should identify 
the areas of managerial flexibility, or the strategic opportunities built-in in the project and which 
the investor could provide. The flexibility is needed to hedge against technical and market 
uncertainties. Out of the three main steps of ROA process, strategic analysis is the most 
subjective step. The analysis defines the characters of the options provided, necessary to quantify 
their value in the later stage of quantitative analysis. In fact, the type and the algorithms that 
synthesize the condition of exercise are necessary to identify for each option.  
First of all, on the strategic analysis stage is important to identify the potential market 
drivers, for example, unmet customer’s needs that influence the process commercialization of the 
company’s product. It is also needed to forecast the information about the future cash flows by 
making realistic assumptions about the size of the market, the market share, and the price of the 
product. In some cases, it is possible to obtain the information about similar deals in the industry. 
The way of exit is also matters, the company may establish manufacturing on its own facilities or 
it can sell the technology license to the another company which is the most popular case.  
When entering into the license agreement the type of the contract is also matters. In some 
situations, the startup could receive royalty payments during the whole period of the technology 
being on the market. The other case is when buyer of the license is guaranteeing to finance the 
R&D stage. 
For biotechnological projects, the main source of flexibility is hidden in the R&D stage. 
The given step of the project can be divided into several phases and the milestone approach is 
usually used to control its progress. An initial investment is similar to the purchasing of an 
option on a future investment. The decision makers also have the option to stop or defer the 
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project at the end of each phase. Therefore, each phase is an option that is contingent on the 
earlier exercise of other options. If the project is a technical success, then it creates the option to 
make a significantly larger investment in the continuing project with relatively higher expected 
net benefit. If the project fails to achieve the technical success, then there is no need to commit 
any further resources, and therefore, the downside risk is limited to the initial investment cost of 
the R&D phase. It is also important to mention that if one phase of the R&D process was not 
successful, managers have the option to defer the project to improve the initial product so that it 
can pass through that stage. 
In the beginning of the strategic analysis, it is useful to build the decision tree of the 
project that will include the most important milestones. The weighted average value of the 
project that will be obtained after decision tree analysis is a good proxy for investment analysis. 
However, one should not forget that decision tree doesn’t evaluate the full range of the options 
of the project. 
2.2 Risk analysis 
Every technological startup is the subject for a big number of risks that have different 
nature. Of course, biotechnological startups and more specifically biomedical startups have its 
own specifics that should be considered. The specifics mainly refer to the process of 
development and commercialization. 
According to Schwartz and Moon (2000), there are three main types of uncertainties in 
pharmaceutical R&D process: technical uncertainty associated with the success of the R&D 
process itself, an exogenous chance for obsolescence, during and after the development process 
and there is uncertainty about the value of the project on completion of the R&D. The former 
uncertainty refers to firm-specific risk and two latter refer to the risk of commercialization or 
market risk.  
As a result, two broad groups of risks for biotechnological startup company can be 
identified: technological risks that affect the capability of the project to pass all the development 
milestones and commercialization risks that are connected with the market success of the 
product. These two groups of risks are not correlated with each other.  
2.1.1 Technological uncertainties  
Biotechnology is characterized by the long process of product development. It can take as 
around a decade to get a new drug on the market in developed countries. In emerging economies 
such as Russia, this process is not so time consuming but still requires a considerable time. 
Anyway, there are typical milestones that can be implied to every biotechnological project. 
 31 
The typical process of new biomedical development includes concept development, 
analysis of optimal characteristics of products which include computer modeling and toxicity 
check, pre-clinical studies where new drugs are tested on animals, synthesis of pilot pieces for 
the clinical studies and the clinical studies that have four stages.  
The first stage of clinical studies is the first trials on people, which are aimed to find the 
optimal dose for the components of the drug. The given trials are aimed to indicate tolerance, 
safety, and presence of the therapeutical effect on the wholesome body. On the second step, 
clinical effect is tested on people with the certain disease again to prove the sufficiency of 
product which is tested. 
The third stage is the mass trial of people with the certain disease. It is usually the most 
time consuming and the most expensive period of clinical study. Before the third stage, the entity 
which product is being tested should produce the required amount of samples, usually around 
one thousand. On the results of this stage, the government body that is in charge might confirm 
or decline the registration of new drug.  
The last stage is conducted after obtaining the license when the drug is already on the 
market. These trials are aimed to determine the difference of the product comparing to other 
drugs on the market in a particular niche and hidden risk factor that were not described during 
the previous studies. 
To sum up, there are four important technological milestones for the biotechnological 
project (Table 2).  During each step, there is a likelihood to fail and to continue. The probability 
of failure can be obtained using the Delphi method the anonymous survey of the experts who are 
working on the project and on the projects with similar characteristics. 
The length of the steps of the development process is also matters. The data can be 
obtained from the web-site of Association of Clinical Trials Organizations (ACTO) that annually 
publishes the numbers for the duration of the clinical process. The average number of days to 
obtain the license from 2005 to 2015 is 116 days (Clinical Trials in Russia, 2016). 
Figure 3. The process of biotechnological R&D. 
 
Source: Association of Clinical Trials Organizations 
Conceptdevelopment Analysis	of	optimal	characteristics Preclinical	studies Cliniclas	studies	(4	steps)
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2.1.2 Commercialization uncertainties  
The biotechnological industry consists of ventures that are using living organisms or 
molecular or cellular techniques to provide medicines, food and services to meet human needs. 
There are thousands of small firms in biotech industry, whose R&D activity shapes the overall 
industry. Mergers and acquisitions happen very frequently in this market and are used as an exit 
strategy for those smaller biotech firms who often have financial difficulties, such as few or no 
marketable products and low cash-to-sales ratios.  
Early-stage companies in the biotech industry face market uncertainties that should be 
considered in valuation. Those uncertainties depend not only on the stage of development and 
the experience of the company, but also the types of drugs being developed. There are several 
type of main specific risks in biotechnological industry, they were summarized in Bratic et al, 
2014 and will be discussed in following paragraph. 
Table 2  
Commercialization risks in biotechnological industry 
 
The risks Impact 
Government regulation 
After the whole technological process there is a risk for 
biotechnological company in not obtaining the license. 
Risk of litigation 
 
The commercianalization of a drug can be blocked by the law. 
Risk of estimating the patient 
population 
Can lead to misevaluation of demand. 
Risk of biosimilars 
There is a risk that another research unit will find a better 
solution to a problem that addressed by the venture’s drug. 
Risk of fake drugs 
The large amount of fake drugs has a downward effect on 
commercianalization potential of a new drug. 
Risk of different legal 
environment 
If the company selling its products to another country more 
likely that it will require additional examinations and 
confirmations. 
Source: Bratic et al 2014 
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Government regulation 
A newly created chemical or biological entity in every developed or developing country 
should overcome numerous regulatory hurdles. In Russian Federation as it was discussed above 
the procedure of drug approval takes around 120 days and consists of 5 stages including the 
expertise of all documents and clinical research and ethical expertise.  
Moreover, a venture needs to receive a special license, which is given for 5 years only if 
venture has approved production facilities and certified well-trained personnel. According to 
open data of Federal Service for Surveillance in Healthcare of Russia only 3% of total amount of 
licenses that were requested in 2015 were denied but at the same time, 18% of total requests to 
extend the license were canceled. So there is always the risk not to obtain regulatory approval. 
Risk of litigation 
Litigation risk is another area for consideration when valuing early-stage biotech 
companies. In spite of extensive risk management efforts of pharmaceutical companies, there has 
been a rise in the number of settlements for violations of a variety of laws in the last two decades 
abroad and in Russian Federation. 
Risk of estimating the patient population 
The actual number of patients that need to be treated, as compared to an extrapolated 
estimated prevalence, is often uncertain. The mistakes in estimations can be related to the fact 
that prevalence studies are usually done in regions of higher prevalence and usually based on 
hospital data. The misevaluation of the demand, of course, has a significant effect on forecasted 
revenues. 
Risk of biosimilars 
The risk of “Biosimilar” drugs is an important factor and should be considered. There is 
always the uncertainty that another research unit will find a better solution to a problem that 
addressed by the venture’s drug. Moreover, another company may just produce a cheaper 
generic alternative. This sphere is well regulated in recent time (Brtatic et al. 2014) but there is 
always back doors for generic producers. 
Risk of fake drugs 
Ernst & Young observed that as of 2008, counterfeit drugs accounted for approximately 
10 percent of the world’s pharmaceutical product supply. This problem is very important for 
emerging markets where there is a lack of normative regulation. Counterfeit biologics are 
extremely challenging to detect, and they are extremely vulnerable to environmental 
degradation, more so than other drugs.  
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Risk of different legal environment 
The company from Russia that aims to sell its products for example in     German market 
will be needed to obtain the commercial license and pass through the whole stages of clinical 
trials that are needed in the another country. Hanse, there is an additional risk of not obtaining 
the license and that the procedure of passing through clinical trials will temporize. 
2.3 Quantitative analysis 
2.3.1 DCF valuation 
The first stage of the ROA process is the estimation of the Net Present Value of the 
project. The estimating of a discount rate is the essential step of DCF analysis. There are some 
widespread methods of obtaining the discount rate such as WACC or CAPM but they are not 
suitable for technological startups. One of the few reliable approaches in case of technological 
projects is the cumulative method (Managarov, 2011) where discount rate is calculated using the 
following formula: 3 = 34 + ? + 32																																																																			(5) 
Where, r is the discount rate, rf is the minimal discount factor or risk-free rate, I is the 
inflation rate, and rp is the coefficient that considers the investment risk of the project. The risk-
free rate is needed not only for DCF valuation but also for the real option valuation using the 
binomial approach so it should be calculated. Russian government bond yield at the time of the 
research is 9,34% (Moex.com, 2016) but due to the unstable economic situation, the country 
default spread should be considered. According to Damodaran (2016), the Russia’s rating based 
default spread currently is 2,77%, so the risk-free rate is equal to 6,57%. 
The annual inflation rate in 2016 according to the forecasts of Ministry of Economic 
Development of Russian Federation is estimated to be 12%. The risk premium for innovation 
development is very high. The risk is increasing when the R&D process is conducted by several 
organizations, there is an uncertainty about demand, prices and absorption of the technology.  
2.3.2 Decision tree analysis 
The decision tree method enables to estimate the value of the project with managerial 
flexibility. The method is basically the graphical representation of the sequential decision 
making process. Real options approach uses decision trees method as the starting point of the 
analysis. However, decision tree valuation is discrete in time, and doesn’t capture full flexibility 
of the project.  
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To estimate the Expected Net Present Value (ENPV) it is needed to determine the present 
value of all possible end points and then multiply them by the respective cumulative 
probabilities. Each stage of the R&D process has its probability to pass as well as there are 
several outcomes of commercialization that have their own distribution. Normally, a constant 
discount rate is applied to find value of the project using the decision tree method (Steffens, 
2007). The estimation of Expected Net Present Value is conducted using the formula 6: 
A%BC = DEFG,I(1 + 3)I ∗ 2G + EEFL,I(1 + 3)IMLN'MGN' ∗ OL																																								(6) 
Where, i is the index of stages, 2G is the conditional probability to pass the stage i, r is the 
discount rate for development cash flows, t is the time of the project development, DEFG,I is the 
expected development cash flow at time t given that i stage is the end stage, j is the index of 
market state at the time of commercialization, EEFL,I  is the expected commercialization cash 
flow at time time t and the market conditions j, and OL is the probability that market will be in the 
state j. The typical decision tree for biotechnological development is presented on the figure 
Figure 4. Decision tree for biotechnological development. 
 
Source: Kellog, Charnes, 2000 
2.3.3 Real options analysis  
As it was discussed in the previous chapter the binomial real options approach doesn’t 
require sophisticated continuous-time stochastic calculations but allow scenario planning 
techniques to be integrated to determine possible development paths for the value of the 
underlying R&D projects. As scenario planning is one of the most common long-term planning 
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tools in corporate practice, the binomial approach has the potential to be implemented in the 
practice of investors. 
The model by Cox, Ross, and Rubenstein is used to form a binomial lattice. The first step 
of the binomial model is to form evolution lattice of the underlying asset. It is assumed that in a 
small time interval Δt the price may change in only two directions:  u (u > 1) times if the price 
will rise and d (d < 1) times if the price will go down. At the end of the first stage, the result is 
the value of the underlying asset at any period of time. Then, the option is calculated using the 
process of backward induction. Figure 4 shows the example of binominal tree with the 
underlying asset S, which is transformed into the tree with option value C: 
Figure 5. Binomial trees with evolution of underlying asset and corresponding option values. 
 
      S*u^3         C3,uuu 
    S*u^2         C2,uu   
  S*u   S*u^2*d 
 
 
 
 
   
 
  C1,u   C3,uud 
S   S*u*d   C0,0   C2,du   
  S*d   S*u*d^2   C1,d   C3,udd 
    S*d^2       C2,dd   
      S*d^3         C3,ddd 
t=0 t=1 t=2 t=3   t=0 t=1 t=2 t=3 
Source: Cox, Ross and Rubinstein (1979) 
The initial binomial lattice is building only with up (u) and down (d) factors. The 
formulas are:  
Q = *R SI; 	& = *,R SI = 1Q																																																								(7) 
Where <t = length of binominal period and σ = volatility.  As it was discussed in the 
first chapter, the volatility of the technological project is typically based on its market 
performance that is affected by the external factors. Following Kellog et al 2000 in this research 
volatility is estimated using the formula 8. 
: = 1] ln ℎ_																																																																						(8) 
Where l is the time period, h is the maximum value for the project cash flows, A is the 
value of the underlying asset. The idea is that we want the value of the project to grow from A to 
the maximum value of h after l time intervals. The natural log is used for volatility estimation to 
make it follow the exponential Brownian Motion stochastic process because the binomial model 
requires it as a fundamental assumption. The binomial period is the time interval in which the 
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price of an underlying asset is changing. For example, after the first-month value of the project 
may either increase or shrink by 10% and so on. 
After the lattice for underlying asset is formed we can calculate the option value using the 
process of backward induction. Values are rolled back using the risk-neutral probability. That are 
probabilities of future outcomes adjusted for risk, as the assumption of the binomial model is that 
investors are neutral towards risk. The assumption is needed to price the asset based only on its 
expected payoffs. The formula for risk-neutral probability is presented below: 
2 = * -a,b ×SI	 − &Q − & 																																																																(9) 
Where rf is the risk-free rate, D is the dividend yield, t = length of the binominal period, u 
is the up state and d is the down state. The binomial model was initially developed for pricing of 
financial options so the dividend yield was used to properly assess the price of the stock. 
However, in real options analysis, the dividend yield is not used. Finally, the general formula to 
find the value of each node of the lattice is: 
Ee,G = 2×ELf',G + 1 − 2 ×ELf',G*-a×gI 																																																(10) 
Sequential Compound Option 
According to the results of the first chapter, the most accurate way to estimate the 
flexibility value of the biotechnological R&D development is to use the sequential compound 
rainbow option model. The compound option exists when the project has multiple stages and the 
latter phases depend on the success of previous ones. To find the value of the project it is needed 
to find a value of several sequential European options. The first step of building the sequential 
compound option is not different from any other ROA model. It includes calculation of up and 
down factors and the underlying asset lattice. On the table below there is the lattice of underlying 
asset S. 
Figure 6. Lattice for the underlying asset. 
      S*u^3 
    S*u^2   
  S*u   S*u^2*d 
S   S*u*d   
  S*d   S*u*d^2 
    S*d^2   
      S*d^3 
t=0 t=1 t=2 t=3 
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The underlying asset is typically the present value of project cash flows. After building 
the first lattice the analysis requires the calculation of the longer-term option first and then the 
shorter-term options because the value of the option is based on the value of previous one. So 
there are as many lattices as stages in the project. If for example the project has two stages, the 
first stage duration is the two time intervals and the second stage start after the realization of the 
first and lasts the one time interval the following lattices should be estimated:  
Figure 7. Example of the lattice for the first stage. 
      C3,uuu 
    C2,uu   
  C1,u   C3,uud 
C0,0   C2,du   
  C1,d   C3,udd 
    C2,dd   
      C3,ddd 
t=0 t=1 t=2 t=3 
 
Figure 8. Example of the lattice for the second stage. 
    C2,uu 
  C1,u   
C0,0   C2,du 
  C1,d   
    C2,dd 
      
t=0 t=1 t=2 
The value on each node of the lattice for the first stage depends on the underlying asset 
but values of the second lattice depend on the values from the previous stage. At the end of each 
stage, the manager has a choice to continue the project or to defer the investments. So the value 
of EG,L is the maximum between investing and keeping the option open. Cj,k = max 	 EG, Lf' − ?noI ∗ pI; 2×E Gf',L q + 1 − 2 ×E Gf',L g ∗ *,-. SI 					(11) 
Where EG, Lf'  is the value of the underlying asset taken from the previous lattice, ?noI 
are investments that are required at time t and pI is the probability to continue to the next stage, p 
is the risk-neutral probability, E Gf',L q is the value of underlying asset in the upper state in the 
same lattice, rf is the risk free rate, and <t is length of binominal period. 
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Summary  
The goal of this chapter is to present the methodology for real options analysis of 
biotechnological startups. The ROA process normally includes three steps: Strategic analysis 
Risk analysis, and Quantitative analysis. 
The strategic analysis is needed to identify the areas of managerial flexibility, or the 
strategic opportunities built-in in the project and which the investor could provide. In the case of 
biotechnological development, this flexibility is that investor may choose to infuse capital in 
stages. If the one stage was not successful investor may choose to defer or abandon the project. 
The risk analysis is required to properly estimate the uncertainties of the particular 
project. These uncertainties are then incorporated into the real options model. Each 
biotechnological development has two main categories of uncertainties: Technological 
uncertainties and Commercialization uncertainties. There are typically four milestones of 
biotechnological R&D process: concept development, analysis of optimal characteristics of the 
product, pre-clinical studies where new drugs are tested on animals, synthesis of pilot pieces for 
the clinical studies and the clinical studies that have four stages. Every step has the probability to 
pass that is included in the Decision tree analysis and in the ROA as the parameter. 
The commercialization uncertainties are individual for every technological project. 
Nevertheless, there are common market risks for biotechnological projects such as Government 
regulation, Risk of litigation, Risk of estimating the patient population, Risk of biosimilars, Risk 
of fake drugs, Risk of the different legal environment. The given risks, as well as those that 
apply for each case specifically, influence the cash flow volatility of the project.  
The DCF valuation is the first step of real options analysis. To estimate the cost of capital 
for technological development the cumulative method is used.  The decision tree approach is the 
alternative method to find the value of the technological project. It enables to consider the option 
to abandon but doesn’t treats properly the market risk and doesn’t take into consideration the 
possibility to defer the investment. However, the method is used to build the strategic tree of the 
project. 
To find the real option value the sequential compound rainbow option model is used. The 
word compound means that the value of one option depends on the previous option. For 
example, in the case of biotechnological development, the value of the first stage depends on the 
success of further stage. This model allows finding the value of an option with two sources of 
uncertainty so it is called a rainbow.  
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CHAPTER 3. CASE STUDY 
The purpose of this chapter is to implement the methodology of real options analysis to 
the project PolySeed from the portfolio of North West Technology Transfer Center (RUSNANO 
group) in order to solve the particular managerial problems such as valuation of the project and 
reducing of risks. The results of given case study can be applicable to other biotechnological 
projects.  
3.1 Description of the project 
PolySeed is the fundamentally new technology for manufacturing polymer micro-
sources, based on the iodine adsorption effect into polymers. These polymer micro sources can 
be used in the cancer treatment method called “brachytherapy” and they are better than micro 
sources that are currently used. The benefits of “PolySeed” micro sources are: 
– The simplicity of the production cycle - the developed technology eliminates the complex 
manufacturing operations while maintaining the physical properties of the mineral; 
– Lower cost - there is no need to use expensive materials (titanium housing, gold or silver 
marker) for the production of micro sources; 
– The increased specific activity of micro sources and the ability to make different shapes; 
– Expanding the range of measurable LDR-brachytherapy diseases - using PolySeed will 
lead to the expansion of the number of Diseases treatable by low-dose brachytherapy. 
Besides prostate cancer, surgery may be the treatment of breast cancer, eye cancer, 
esophagus, lung, trachea, and bronchus. In the long term option for targeted delivery of 
drugs can be developed; 
– Reduces injury rate of operations - because micro sources used will be manufactured 
entirely from biodegradable materials, their presence in the patient's body will be limited 
to a certain period, after which the Micro Source dissolved, while not causing any harm 
to the body. 
3.1.1 Market of brachytherapy 
Brachytherapy - is a local form of radiotherapy in which the Micro Source of radiation is 
introduced into the affected organ for some time (HDR brachytherapy) or placed on a permanent 
basis in the patient's body (low-dose brachytherapy). 
In the treatment of prostate cancer brachytherapy technique has become the most popular 
and replaced the surgical method and EBRT method because of the similar efficacy, but lower 
costs and injury rate. The cost of surgical intervention for brachytherapy remains high. 
According to the Institute for Clinical and Economic Review (ICER), cost of brachytherapy in 
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the treatment of prostate cancer in the US in 2010 was USD 35.1 thousand, and the cost of 
external beam radiation therapy - USD 59,5 thousand. 
The world medical statistics testifies to the annual increase in the number of new cases of 
cancer worldwide - around 13 million. Most of the malignant tumors are radiosensitive. Over the 
past decade, the number of men annually detected with prostate cancer increased by an average 
of 7.6%. The absolute number of newly diagnosed prostate cancer has increased since 2001, 
more than 2 times: from 12.8 thousand to 28.6 thousand the case of the time. This type of disease 
accounts for 12.4% of the total of detected cancers in men. 
HDR brachytherapy method has become a primary therapy to be applied for the treatment 
of localized malignant tumors in remote organs such as the prostate gland, the esophagus, 
stomach, pancreas, kidney, bladder, uterus, trachea, bronchi, and lungs. In the total volume of 
newly diagnosed cancers, there are more than 40% that can be cured by low-dose brachytherapy. 
Today, the capacity of the Russian market of HDR brachytherapy is estimated at about 3 
thousand micro sources sets per year, in Europe 12 thousand in the US -50 thousand. When 
selling price of micro sources in USD 130, the entire market is estimated at USD 507 million. a 
year, Russia USD 23 million. per year. The number of micro sources implantation into the 
prostate gland is growing 2-3% annually. 
Figure 9. Market volume for low dose brachytherapy in 2015. 
 
 
Source: Cancer Treatment Centers of America 
In Russia the state allocates quotas for operations: in 2013, the number of quotas for low-
dose brachytherapy was 737, an increase of 100 quotas than in 2012. Thus, the state provided 
about 25% of the potential demand. According to the Association of Russian Brahitherapists, 
there are 17 medical centers in our country that have brachytherapy services, with leading clinics 
USAUSD	390	mln.77%
RussiaUSD	23	mln.5%
EuropeUSD	94	mln.18%
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in the segment of low-dose brachytherapy is FGUZ KB №8 FMBA of Russia (Obninsk) and the 
Clinical Hospital №122 them. LG Sokolova FMBA of Russia (St. Petersburg). 
Figure 10. Allocation of low dose brachytherapy surgeries in Russia (2015). 
 
Source: Association of Russian Brahitherapists 
3.2 Investment analysis of the project 
3.2.1 Strategic analysis of the PolySeed project 
In the case of the PolySeed project as well as in the case of almost each biotechnological 
development the investors have the option to infuse capital in stages. To consider the given 
option, the project development process was divided into stages according to a methodology that 
was presented in the second chapter. The typical structure of the biotechnological development 
includes four main stages: analysis of optimal characteristics of products which include 
computer modeling and toxicity check, pre-clinical studies where new drugs are tested on 
animals, synthesis of pilot pieces for the clinical studies and the clinical studies that have four 
stages. In this particular case, the following structure is applied. The project aims to develop the 
micro sources to carry the nuclear materials for cancer treatment, so the second stage includes 
the research with nuclear materials.  
The crucial part of the strategic analysis of the biotechnological project is to split the 
costs between stages of the development as well as estimate the duration of every step. In this 
case, the duration of clinical tests was taken from the ACTO database. According to the 
database, the average duration of clinical tests in Russia is 130 days. The durations of other 
stages was obtained from the interviews with the investment managers of NWTTC that have 
experience of conducting the similar projects. The probabilities to succeed on every step was 
derived from interviews with experts group who are working on this or similar projects The 
results summarized in the table above. 
Table 3 
2 263
737
Paid 
surgeries
75 %
Quotas 
25%
 43 
Stages of the PolySeed  project 
Stage Duration (month) 
Costs (In thousand 
roubles) 
Probabilities 
Research of 
technology’s optimal 
parameters 
8 -2850 0,7 
Research with 
materials 
6 -4000 0,7 
Production of 
necessary amount of 
materials for clinical 
trials 
2 -300 0,9 
Clinical trials 4 -1850 0,6 
Source: Interview with experts from NWTTC 
The full range of real options that are typical for biotechnological development is 
presented in the PolySeed project. For the NWTTC, the project clearly embraces the growth 
option. There is a possibility to abandon the project at every stage. The equipment is supposed to 
be rented through the life of the project so the project doesn’t have any salvage value. Managers 
also have an option to defer the project in case of any technological stage will not be successful. 
In this scenario rather than shutting down the project, it is more sensible to make adjustments in 
technology and continue the development. 
3.2.2 Risk analysis of the PolySeed project 
The probability of passing every step was assessed by the survey of technical experts who 
are in charge of the process realization. The another source of risk is the volatility of project’s 
cash flow. Commercialization of the technology is planning to be achieved through the sale of 
Russian and international patent rights on the production technology to create polymer 
radioactive sources and for utility installation model to interested strategic investors. The leading 
manufacturers of micro sources in Russia and worldwide are:  
– Russian manufacturer of micro sources JSC "NanoBrahiTek" Dubna (shareholders: OJSC 
«RUSNANO», Eckert & Ziegler BEBIG s.a, NADEX MAX LTD, OOO "Santis"); 
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– The world's largest manufacturers: Eckert & Ziegler BEBIG, Varian Medical Systems, 
Nucletron (Elekta), GE Healthcare. 
One of the main risks of PolySeed project is the threat from similar technologies. In table 
4, the competitive position of the project is summarized. There are two rival technologies on the 
market are IsoSeed® I-125 and Oncoseed. Their main advantage is they already well established 
on the market. However, PolySeed technology has an advantage in terms of price as it uses 
cheap polymer materials instead of titanium. 
Table 4 
Competetive position of the PolySeed project 
Name of 
technology 
Manufacturer Stage Material 
Shape and 
size 
Radiactivity 
(mCi) 
Price 
IsoSeed® 
I-125 
Eckert & 
Ziegler 
BEBIG 
On the 
market 
Ti, Ag, 
Au 
 
Cylinder 
Length: 
4.5 mm ± 
0.2 mm; 
Diameter: 
0.8 mm ± 
0.04 mm 
0.203-1.687 
 
On request 
Oncoseed 
Oncura (GE 
Healthcare 
unit) 
On the 
market 
Ti, Ag, 
Au 
 
Cylinder 
Length: 
4.5 mm; 
Diameter: 
0.8 mm 
0.191-1.016 
 
On request 
PolySeed 
Project’s 
group 
Start of the 
development 
Medical 
polymer 
Sphere, 
cylinder 
and so 
forth. 
Typical 
size: 0.5-
0.8 mm 
0.10-2.00 
 
Lower than 
price of 
competitors 
Source: North West Technology Transfer Center   
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The commercialization of the technology is planning to be achieved through the disposal 
of patent rights in Russia and abroad. The capacity of the Russian market of low-dose 
brachytherapy is estimated at about 3 thousand sets (1 set = 15 micro sources) per year in Europe 
- 12 thousand in the US - 50 thousand. The commercialization of the technology to foreign 
countries is impeded by the fact that technology should overpass the whole medical control. 
Moreover, the international companies will be ready to use the technology if it will recommend 
itself on the market. Nevertheless, the main goal of the project is the disposal of patent rights to 
international companies. 
The assumptions about the price of the technology are based according to realistic market 
data that are: 
– Developed polymer micro sources have no analogs on the market; 
– Developed micro sources will have a number of competitive advantages, from the lower 
cost of production, ending with the increased specific activity of micro sources; 
– In 2009 JSC "NanoBrahiTek" acquired the Eckert & Ziegler BEBIG license to 
manufacture successfully passed clinical trials titanium brachytherapy sources for the 
USD 2 000 000; 
– Low-dose brachytherapy market is growing at a pace of 3.2% in real terms (According to 
estimations of Russia’s brachytherapy center). 
The assumption about the price of the technology was made based on the interview with 
managers of NWTTC and the analysis of the market. The most likely scenario is that PolySeed 
will obtain 15 millions of rubles for the technologic patent, also there is a possibility to get 60 
millions of rubles in the case of the favorable market conditions and 0 in the case of the failure in 
the market. 
Table 5 
The revenue assumption 
Revenue assumption 
In thousands rubles 
Probability Revenue from selling the 
patent rights 
0,6 15000 
0,25 60000 
0,15 0 
Source: Interview with managers of NWTTC, market analysis 
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3.2.1 DCF valuation of the PolySeed project 
As it was discussed in the second chapter the discount rate was found following the 
cumulative method. The annual inflation rate was assumed as 13%, the risk-free rate is 6,5% and 
the project risk premium is 30% that can be explained by the high risk of the project and internal 
norms of the NWTTC. The discount factor that was used in the analysis is equal to 50%. The tax 
rate is assumed to be 20% for the entire life of the project. The revenue of the project was taken 
from the most likely scenario. The process of Net Present Value calculation is presented in the 
table below. The detailed table with computations is in Appendix 1. 
Table 6 
DCF valuation of PolySeed project 
Starting date of the project 01.10.16       
Expected duration 20 month       
In thousands rubles 2016 2017 2018 Total 
Contractor's fee -1 775,00 ₽ -5 475,00 ₽ -1 800,00 ₽ -9 050,00 ₽ 
Administrative cost  -60,00 ₽ -240,00 ₽ -60,00 ₽ -360,00 ₽ 
Patent registration     -200,00 ₽ -200,00 ₽ 
Salary budget and the social tax -17,00 ₽ -68,00 ₽ -23,00 ₽ -108,00 ₽ 
Operating expenditures -1 852,00 ₽ -5 783,00 ₽ -2 083,00 ₽ -9 718,00 ₽ 
Rent and following acquisition of 
equipment -23,00 ₽ -90,00 ₽ -1 388,00 ₽ -1 501,00 ₽ 
Capital expenditures -23,00 ₽ -90,00 ₽ -1 388,00 ₽ -1 501,00 ₽ 
Income from selling the patent 
rights     15 000,00 ₽ 15 000,00 ₽ 
Income tax (1,7% month) -93,75 ₽ -1 174,60 ₽ 923,55 ₽   
FCF -1 843,13 ₽ -5 684,69 ₽ 11 529,61 ₽   
DCF -1 228,75 ₽ -3 158,16 ₽ 4 702,27 ₽   
NPV 316,27 ₽       
IRR	  51% 		 		 		
Source: Made based on the previous analysis and data provided by NWTTC 
The discounted cash flow analysis shows that present value of the project is slightly 
above zero. The internal rate of return is just on the same level with what investors want to gain 
from such types of projects. After such results, the project is at risk of not being approved by the 
investment committee so the flexibility of the project should be taken into the account. 
3.2.2 Decision tree analysis of the PolySeed project 
The decision tree method was used to estimate the Expected Net Present Value of the 
project. The main advantage of the method comparing to DCF is that it captures managerial 
flexibility. It estimates the value of the option to abandon the project in case of technological 
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failure. The method implies that the revenues occur only in case of passing all the technological 
stages 
To calculate the ENPV of the PolySeed project the data obtained during the strategic 
analysis was used. The project was divided into four stages. Probabilities to pass each stage were 
derived from a survey of experts who had the experience of launching the similar projects. The 
overall costs of the project were split between the stages. On the table below there are inputs and 
results of the decision tree analysis. The decision tree itself is presented in Appendix 2. 
Table 7 
Decision tree analysis 
Stage    
Cumulative 
probability of 
negative result 
Probabilities 
of CCF NPV P*NPV 
In thoussands roubles           
Research of 
technology's optimal 
parametrs  
 
0,3 
 
-2 807,83 ₽ -842,35 ₽ 
Research with 
nuclear materials.  
 
0,21 
 
-4 597,45 ₽ -965,47 ₽ 
Production of 
necessary amount of 
materials for clinical 
trial.  
 
0,0245 
 
-4 808,00 ₽ -117,80 ₽ 
Clinical Tests 
 
0,1862 
 
-6 237,06 ₽ -1 161,34 ₽ 
Approval Optimistic 
 
0,25 20 429,60 ₽ 5 107,40 ₽ 
  Most likely 
 
0,6 316,27 ₽ 189,76 ₽ 
  Pessimistic 
 
0,15 -6 237,06 ₽ -935,56 ₽ 
        ENPV 1 274,65 ₽ 
Source: Made based on the previous analysis and data provided by NWTTC 
The decision tree analysis gives the higher value of the project than DCF method because it 
incorporates the option to abandon and make possible to estimate the distribution of project’s 
cash flows based on different scenarios. However, it doesn’t capture the full flexibility that 
investors have.  
3.2.3 Real options analysis of the PolySeed project 
For the purpose of the analysis, the present value of revenue was taken as the underlying 
asset for the binomial tree. It was estimated as 6,553 millions of rubles. The volatility of the 
project’s cash flow was estimated using the formula presented in the second chapter where h is 
60 millions of rubles – the maximum amount of money that the project can obtain, l is the 
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duration of the project – 20 months, and A is 6,553 the present value of the project. The 
volatility of the project was estimated as 27%. The binomial period was taken as 2 so we 
assumed that the price of the technology will change every two months.  
The sequential compound rainbow option captures the flexibility of managers to invest in 
the next stage or keep the option open.  So at each node, there is a choice between investing and 
waiting. The decision rule is the following: ?4	 EG, Lf' − ?noI ∗ pI > 2×E Gf',L q + 1 − 2 ×E Gf',L g ∗ *,- SI →																																									5ℎ*	tno*uvw3u	uℎwQ]&	23w!**&	xtvℎ	vℎ*	23wy*!v																												     (12) 
Where EG, Lf'  is the value of the underlying asset taken from the previous lattice, ?noI 
are investments that are required for the stage t and pI is the probability to continue to the next 
stage, p is the risk neutral probability, E Gf',L q is the value of underlying asset in the upper state 
in the same lattice, rf is the risk free rate, and <t is length of binominal period. The first part of 
equation symbolizes the value of investments and the second part the value of keeping the option 
open. 
After building the lattice with the evolution of the underlying asset, the four sequential 
phases are evaluated using the described above decision rule, starting with the latter stage. The 
lattices are presented in the Appendices 3, 4, and 5. In Appendix 6, there is a strategic lattice 
built based on the previous binomial trees. The prices of options for each stage are summarized 
in the following table. The option price for the first option reflects the flexibility value of the 
whole project. The extended value of the project according to ROA approach is the value of the 
compound sequential option, i.e. the option price of the first stage plus the NPV. 
Table 8 
Option values for the sequential stages of the research (In thousands of rubles) 
Stage First stage: 
Research of 
technology's 
optimal 
parameters 
Second stage: 
Research with 
nuclear 
materials. 
Third stage: 
Production of 
necessary 
amount of 
materials for 
clinical trial. 
Fourth stage: 
Clinical Tests 
Option Value 132,5 
 
1399,4 
 
3514,2 
 
2943,6 
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In the given model such options as growth option, the option to abandon the project and 
option to defer were incorporated. The real options approach allows receiving the value of the 
venture at every stage of R&D development. It is the practically useful information because 
commonly before the initiation of the certain development stage managers need to bear the 
certain costs for example for patenting or prototyping. The value of the option shows the 
maximum sum that investors can spend in the beginning of the stage. 
Moreover, managers may use the ROA approach in the decision-making process because 
it uses the volatility of project cash flows that are dependent on the state of the market. So before 
the initiating of the project, managers may use the binomial lattice to see in what of the market 
state they should make investments. The strategic lattice is presented in Appendix 6. 
3.3 Discussion 
In the given research the methodology for investment analysis of the biotechnological 
project was formulated and applied to the specific project from the North West Technology 
Transfer Center. The real options model was adopted for the purpose of the analysis. The 
proposed model suits the process of the biotechnological development because it enables to 
calculate the value of every stage using information about the future sequential options. The 
model is also consistent with the risk-free arbitrage method of valuing options. The proposed 
model may approach not only projects in biotechnological sphere but other technological 
projects that require several steps of development. 
For the investment managers of the particular project, the value of the startup was 
obtained using three methods, the results are summarized in table 9. 
Table 9 
The value of the project obtained using different approaches 
Method used DCF Decision tree ROA 
Value of the project 
(in thousands of rubles) 
316,27 1274 448,77 
Apart from the strictly practical result, this paper provides the comparison of valuation 
methods. The methodology that applied in the paper clearly provides more sophisticated 
approach to value technological project than simple DCF approach. The usage of the decision 
tree method and real options approach enables to estimate the flexibility of the project. 
Moreover, those methods take into account two factors of volatility: technological and market 
that appear to be more precise in terms of risk management.  
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In this research, the real options model was implemented for valuation of the project in 
biotechnological industry. There is a limited amount of works on the given topic in financial 
literature, especially in Russia. The binomial method was used for valuation of biotechnological 
development in Kellog 2000 and Zabolotskij 2008. However, the models of real options that 
were used in this works are slightly different. 
The model of the sequential compound rainbow option was used in Cassimon 2004, 
Herath 2002, and Fujiwara 2015. Nevertheless, there is no the parallel comparison with other 
methods of valuation and the specifics of the real option implementation is rather different. In 
this way, the given paper provides a new glance on the problem of real options implementation 
to the biotechnological industry. 
The research illustrated that DCF analysis tends to give undervalued results because it 
doesn’t deal with density distribution of project’s cash flows. Hence, application of real option 
methods may be extremely useful to value the projects with negative NPV. The decision tree 
approach allows to build a consistent framework of the project and should be used as the first 
stage of real options analysis. However, it doesn’t capture the full spectrum of managerial 
flexibility implied in the project. In a case of PolySeed decision tree doesn’t account for the 
option to keep the project open. 
Both the decision tree and real option methods imply several scenarios for cash flows 
distribution that are more realistic assumption that DCF model has. However, the decision tree 
method is rather simplified because it assumes the discrete distribution of cash flows. Like in the 
case of PolySeed, there are only three scenarios: 60, 15 and 0 millions of rubles. In real options 
analysis, the continuous distribution of cash flows is used so the result is the stochastic variable. 
The latter approach appears to be more reasonable but tends to give lower results in terms of 
valuation. The value of the project obtained with decision tree technique is more than twice 
higher than those obtained using ROA.   
The additional benefit of the sequential compound real options model with multiple 
volatilities is that it estimates the value of every step of the separate project that gives the most 
precise understanding of the development scheme for managers.  
On the basis of the conducted research, it can be concluded that real option is the tool that 
most accurately suits the valuation process of biotechnological startups as it allows to estimate 
the full flexibility of the R&D process. The importance of the tool is obvious for the firms that 
operate in a very uncertain environment like technological ventures. In this research, the 
methodology for conducting ROA in the biotechnological industry is presented. The proposed 
model can be used for projects that have several stages.   
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At that point, it is important to say about the limitations of the sequential compound 
model for valuing real options. Despite that the model very well suits the process of 
biotechnological and other multi-stage developments it is might be problematic to implement in 
other fields because the nature of real options there is different. Secondly, the process of real 
options analysis requires rather sophisticated calculations that managers who are limited in time 
wouldn’t approach. Moreover, there are limitations that are aligned with implementation of the 
binomial model. It was initially developed to work with historic volatilities rather than future 
estimation of cash flows. Despite the implementation of volatility associated with future 
projections of cash flows is scientifically sound it may give the small mistake in the results.     
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CONCLUSION 
The goal of given research was to make recommendations concerning the improvement 
of the investment analysis process of biotechnological projects applying the methodology of real 
options. In order to accomplish this goal, the certain objectives were solved. First of all, the 
overview of existing methods of valuation of technological startups and typical risks of such 
projects were provided. Also, the real option concept and its applicability to the investment 
analysis of technological and biotechnological ventures was reviewed. Then the methodology for 
investment analysis of biotechnological ventures with consideration of real options was 
formulated. Then in order to illustrate the advantages of the method it was applied to the 
particular project. Finally, we propose some recommendations for improvement the process of 
investment analysis of biotechnological startups. 
In the first chapter, the benefits and limitations of the most common methods of valuation 
of technological startups were reviewed. Additionally, the typical structure of the technological 
development and standard risks that are associated with technological companies were discussed. 
The second part of the first chapter is devoted to the literature overview of the real options 
concept and its applicability in the technological and biotechnological sphere. The aim of this 
part was to review the real options models that can be relevant to investment analysis of 
biotechnological projects. 
On the basis of the first chapter, it was determined that the most widespread approaches 
do not value properly the multi-stage projects in which implementation of one phase depends on 
the successful completion of the previous one, which is typical for the biotechnological sphere. 
The risks can be classified as market uncertainties systematic or firm specific and technical 
uncertainties. ROA process includes three main stages: Strategic analysis, risk analysis, and 
quantitative analysis. The binomial (lattice) method and the sequential compound rainbow option 
model are the most accurate to value the biotechnological development. 
The second chapter was devoted to the formulation of the methodology for the 
investment analysis of the biotechnological startups. The strategic analysis is needed to identify 
the areas of managerial flexibility, or the strategic opportunities built-in in the project and which 
the investor could provide. In the case of biotechnological development, the typical flexibility is 
that investor may choose to infuse capital in stages. If the one stage was not successful investor 
may choose to defer or abandon the project. 
The specifics of biotechnological projects were considered in this chapter. There are 
typically four milestones of biotechnological R&D process: concept development, analysis of 
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optimal characteristics of the product, pre-clinical studies where new drugs are tested on 
animals, synthesis of pilot pieces for the clinical studies and the clinical studies that have four 
stages. The commercialization uncertainties are specific for every technological project. 
However, there are common market risks such as government regulation, risk of litigation, risk 
of estimating the patient population, risk of the different legal environment and other. The given 
risks, as well as those that apply for each case specifically, influence the cash flow volatility of 
the project.  
In the part devoted to the quantitative analysis, three methods of valuation were described 
such as DCF method that is basically the first part of the ROA, Decision tree method, and real 
options analysis. The combination of this methods enables to conduct the investment analysis of 
the biotechnological project in an adequate manner. 
Finally, in the third chapter the developed methodology was applied to the real project 
from the portfolio of North West Technology Transfer Centre (RUSNANO group). The 
PolySeed project develops the new technology for manufacturing polymer micro-sources that are 
used in the cancer treatment method called brachytherapy. Strategic and risk analyses included 
the identification of stages of the project, amount of capital that is needed for each stage and 
analysis of the external environment of the project in order to identify the cash flow volatility. 
The quantitative analysis contained the assessment of the project using three abovementioned 
techniques.  
In the result the following recommendations for managers and investors who involved 
into the investment analysis of biotechnological startups are proposed: 
1. The DCF analysis tends to give undervalued results because it doesn't deal either with the 
flexibility that the project has nor with density distribution of project’s cash flows. 
However, it rather simple to implement and is good to obtain the conservative value of 
the project. Moreover, the DCF analysis is the first stage of implementation of the ROA. 
2. The decision tree method allows to build a consistent framework of the project and to 
capture the value of the option to abandon. However, it doesn’t capture the full spectrum 
of managerial flexibility implied in the project and uses the simplified assumption of 
discrete distribution of cash flows. 
3. The real option allows estimating the full flexibility of the R&D process. The importance 
of the tool is obvious for the firms that operate in a very uncertain environment like 
technological ventures because it incorporates the multiple sources of volatility and 
provides the appropriate treatment of risks. Application of real options method may be 
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extremely useful to value the projects with negative NPV because it estimates the value 
of managerial flexibility. 
4. To conduct the real options analysis of the biotechnological venture, the sequential 
compound rainbow option model was implemented. The given model allows to properly 
estimate the flexibility that biotechnological project has. Moreover, the model allows 
finding the value of every stage of the development that represent the marginal 
expenditures for managers. It also provides the strategic lattice of the project’s value that 
is the useful tool in the decision-making. 
There are two main contributions of this papers. First of all, the investment analysis of 
the PolySeed project was conducted. The paper has a practical information for managers from 
NWTTC (RUSNANO group). Secondly, the developed methodology might be implemented for 
investment analysis of projects in the biotechnological sphere and for other multi-staged 
projects. The implementation of the real options tool and its benefits was illustrated on the 
example. The assumptions of the method appear to be the most realistic for the companies 
operating in the uncertain environment among all methods that were described so it definitely 
should be applied for investment analysis of the biotechnological projects. 
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APPENDICES 
Appendix 1: DCF valuation 
 
 
In thousands rubles 01.10.16 01.11.16 01.12.16 01.01.17 01.02.17 01.03.17 01.04.17 01.05.17 01.06.17 01.07.17 
Contractor's fee -592 -592 -592 -456 -456 -456 -456 -456 -456 -456 
Administrative cost  -20 -20 -20 -20 -20 -20 -20 -20 -20 -20 
Patent registration                     
Salary budget and the social 
tax 
-6 -6 -6 -6 -6 -6 -6 -6 -6 -6 
Operating expenditures -617 -617 -617 -482 -482 -482 -482 -482 -482 -482 
Rent and following 
acquisition of equipment 
-8 -8 -8 -8 -116 -125 0 0 0 0 
Capital expenditures -8 -8 -8 0 1250 1250 0 0 0 0 
Income from selling the 
technology license 
                    
Income tax (1,7% month) -11 -11 -11 -8 -8 -8 -8 -8 -8 -8 
FCF -614 -614 -614 -474 -474 -474 -474 -474 -474 -474 
DCF -410 -410 -410 -316 -316 -316 -316 -316 -316 -316 
NPV 316                   
 
  
 61 
   
In thousands rubles 01.08.17 01.09.17 01.10.17 01.11.17 01.12.17 01.01.18 01.02.18 01.03.18 01.04.18 01.05.18 
Contractor's fee -456 -456 -456 -456 -456 -600 -600 -300 -300   
Administrative cost  -20 -20 -20 -20 -20 -20 -20 -10 -10   
Patent registration                -200   
Salary budget and the social 
tax 
-6 -6 -6 -6 -6 -8 -8 -4 -4   
Operating expenditures -482 -482 -482 -482 -482 -628 -628 -314 -514   
Rent and following 
acquisition of equipment 
0 0 0 0 0 -463 -463 -231 -231   
Capital expenditures 0 0 0 0 0 -463 -463 -231 -231   
Income from selling the patent 
rights 
                15000 
Income tax (1,7% month) -8 -8 -8 -8 -8 -19 -19  -9  -9 255 
FCF -474 -474 -474 -474 -474 -1072 -1072 -536 -736 14745 
DCF -316 -316 -316 -211 -211 -476 -476 -238 -327 6553 
NPV                     
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Appendix 2: Decision tree of the PolySeed project 
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Appendix 3: Evolution of the underlying asset of the PolySeed project 
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Appendix 4: The binomial lattices of the forth and the fifth stages  
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Appendix 5: The binomial lattices of the first and the second stages  
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Appendix 6: Strategic lattice for the PolySeed project 
 
		
